Annotation of Sequence Variants in Cancer Samples

King, 2003, Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, 302, 643, 10.1126/science.1088759 Lynch, 1999, Genetic susceptibility to non-polyposis colorectal cancer, J Med Genet, 36, 801 2007, Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, Nature, 447, 661, 10.1038/nature05911 Manolio, 2009, Finding the missing heritability of complex diseases, Nature, 461, 747, 10.1038/nature08494 Dong, 2008, Genetic susceptibility to cancer: the role of polymorphisms in candidate genes, JAMA, 299, 2423, 10.1001/jama.299.20.2423 McClellan, 2010, Genetic heterogeneity in human disease, Cell, 141, 210, 10.1016/j.cell.2010.03.032 Larson, 2012, SomaticSniper: identification of somatic point mutations in whole genome sequencing data, Bioinformatics, 28, 311, 10.1093/bioinformatics/btr665 Aziz, 2015, College of American Pathologists' laboratory standards for next-generation sequencing clinical tests, Arch Pathol Lab Med, 139, 481, 10.5858/arpa.2014-0250-CP 2003, The International HapMap Project, Nature, 426, 789, 10.1038/nature02168 Tennessen, 2012, Evolution and functional impact of rare coding variation from deep sequencing of human exomes, Science, 337, 64, 10.1126/science.1219240 Abecasis, 2012, An integrated map of genetic variation from 1,092 human genomes, Nature, 491, 56, 10.1038/nature11632 Yang, 2010, Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies, Bioinformatics, 26, 2474, 10.1093/bioinformatics/btq452 2014, Database resources of the National Center for Biotechnology Information, Nucleic Acids Res, 42, D7, 10.1093/nar/gkt1146 MacDonald, 2014, The Database of Genomic Variants: a curated collection of structural variation in the human genome, Nucleic Acids Res, 42, D986, 10.1093/nar/gkt958 Gorlov, 2008, Shifting paradigm of association studies: value of rare single-nucleotide polymorphisms, Am J Hum Genet, 82, 100, 10.1016/j.ajhg.2007.09.006 Abecasis, 2010, A map of human genome variation from population-scale sequencing, Nature, 467, 1061, 10.1038/nature09534 Landrum, 2014, ClinVar: public archive of relationships among sequence variation and human phenotype, Nucleic Acids Res, 42, D980, 10.1093/nar/gkt1113 Richards, 2008, ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007, Genet Med, 10, 294, 10.1097/GIM.0b013e31816b5cae Tavtigian, 2008, Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group, Hum Mutat, 29, 1261, 10.1002/humu.20903 Goldgar, 2004, Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2, Am J Hum Genet, 75, 535, 10.1086/424388 Thompson, 2014, Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database, Nat Genet, 46, 107, 10.1038/ng.2854 Easton, 2007, A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes, Am J Hum Genet, 81, 873, 10.1086/521032 Greaves, 2012, Clonal evolution in cancer, Nature, 481, 306, 10.1038/nature10762 Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, 366, 883, 10.1056/NEJMoa1113205 Qi, 2014, Diversity and clonal selection in the human T-cell repertoire, Proc Natl Acad Sci U S A, 111, 13139, 10.1073/pnas.1409155111 Schumacher, 2014, A comparison of deep sequencing of TCRG rearrangements vs traditional capillary electrophoresis for assessment of clonality in T-cell lymphoproliferative disorders, Am J Clin Pathol, 141, 348, 10.1309/AJCP5TYGBVW4ZITR Lee, 2014, Assessment of mutation status in a large series of patients with suspected cytopenias with normal karyotypes and without increased blasts, Blood, 124, 4606, 10.1182/blood.V124.21.4606.4606 Lacey, 2008, Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies, Cancer, 113, 2073, 10.1002/cncr.23808 2013, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N Engl J Med, 368, 2059, 10.1056/NEJMoa1301689 Cervera, 2014, Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia, Am J Hematol, 89, 604, 10.1002/ajh.23702 Patnaik, 2013, Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes, Leukemia, 27, 1504, 10.1038/leu.2013.88 Schnittger, 2012, Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow, Haematologica, 97, 1582, 10.3324/haematol.2012.064683 Kandoth, 2013, Integrated genomic characterization of endometrial carcinoma, Nature, 497, 67, 10.1038/nature12113 Tothill, 2013, Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary, J Pathol, 231, 413, 10.1002/path.4251 Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, 114, 937, 10.1182/blood-2009-03-209262 Fasan, 2013, Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases, PLoS One, 8, e54365, 10.1371/journal.pone.0054365 Jabbour, 2009, Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations, Blood, 114, 2037, 10.1182/blood-2009-01-197715 Mok, 2013, Treating patients with EGFR-sensitizing mutations: first line or second line–is there a difference?, J Clin Oncol, 31, 1081, 10.1200/JCO.2012.43.0652 Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782 Puig, 2014, Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma: a comparative analysis with flow cytometry, Leukemia, 28, 391, 10.1038/leu.2013.217 Wu, 2012, High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia, Sci Transl Med, 4, 134ra63, 10.1126/scitranslmed.3003656 Stead, 2013, Accurately identifying low-allelic fraction variants in single samples with next-generation sequencing: applications in tumor subclone resolution, Hum Mutat, 34, 1432, 10.1002/humu.22365 Chen, 2015, Clinical actionability enhanced through deep targeted sequencing of solid tumors, Clin Chem, 61, 544, 10.1373/clinchem.2014.231100 Lin, 2014, IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution, Am J Hematol, 89, 137, 10.1002/ajh.23596 Daber, 2013, Understanding the limitations of next generation sequencing informatics, an approach to clinical pipeline validation using artificial data sets, Cancer Genet, 206, 441, 10.1016/j.cancergen.2013.11.005 Spencer, 2013, Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data, J Mol Diagn, 15, 81, 10.1016/j.jmoldx.2012.08.001 Forbes, 2011, COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer, Nucleic Acids Res, 39, D945, 10.1093/nar/gkq929 Bell, 2005, Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR, Nat Genet, 37, 1315, 10.1038/ng1671 Metzeler, 2011, TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study, J Clin Oncol, 29, 1373, 10.1200/JCO.2010.32.7742 Greenberg, 2012, Revised international prognostic scoring system for myelodysplastic syndromes, Blood, 120, 2454, 10.1182/blood-2012-03-420489 Malcovati, 2013, Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet, Blood, 122, 2943, 10.1182/blood-2013-03-492884 Solary, 2014, The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases, Leukemia, 28, 485, 10.1038/leu.2013.337 Ko, 2010, Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2, Nature, 468, 839, 10.1038/nature09586 Genovese, 2014, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, N Engl J Med, 371, 2477, 10.1056/NEJMoa1409405 Gaidzik, 2012, TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group, J Clin Oncol, 30, 1350, 10.1200/JCO.2011.39.2886 Smith, 2010, Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value, Blood, 116, 3923, 10.1182/blood-2010-03-274704 Hu, 2013, Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation, Cell, 155, 1545, 10.1016/j.cell.2013.11.020 Lin, 2014, Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations, Haematologica, 99, 28, 10.3324/haematol.2013.091249 Nibourel, 2010, Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission, Blood, 116, 1132, 10.1182/blood-2009-07-234484 Tavtigian, 2008, In silico analysis of missense substitutions using sequence-alignment based methods, Hum Mutat, 29, 1327, 10.1002/humu.20892 Chan, 2007, Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR), Hum Mutat, 28, 683, 10.1002/humu.20492 Gemovic, 2013, Feature-based classification of amino acid substitutions outside conserved functional protein domains, Scientific World Journal, 2013, 948617, 10.1155/2013/948617 Gonzalez-Perez, 2011, Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel, Am J Hum Genet, 88, 440, 10.1016/j.ajhg.2011.03.004 Kroeze, 2014, Characterization of acute myeloid leukemia based on levels of global hydroxymethylation, Blood, 124, 1110, 10.1182/blood-2013-08-518514 Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213 Weissmann, 2012, Landscape of TET2 mutations in acute myeloid leukemia, Leukemia, 26, 934, 10.1038/leu.2011.326 Kutny, 2010, TET2 SNP rs2454206 (I1762V) correlates with improved survival in pediatric acute myelogenous leukemia, a report from the Children's Oncology Group, Blood, 116, 418a Lindor, 2012, A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS), Hum Mutat, 33, 8, 10.1002/humu.21627 McArthur, 2014, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, Lancet Oncol, 15, 323, 10.1016/S1470-2045(14)70012-9 Landsman-Blumberg, 2014, Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. community-based oncology practices, Clin Colorectal Cancer, 13, 178, 10.1016/j.clcc.2014.05.001 Qu, 2013, Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays, J Mol Diagn, 15, 790, 10.1016/j.jmoldx.2013.07.003 Ding, 2014, The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis, Onco Targets Ther, 7, 387 Bradeen, 2006, Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations, Blood, 108, 2332, 10.1182/blood-2006-02-004580 Cottrell, 2014, Validation of a next-generation sequencing assay for clinical molecular oncology, J Mol Diagn, 16, 89, 10.1016/j.jmoldx.2013.10.002 Jung, 2013, Systematic investigation of cancer-associated somatic point mutations in SNP databases, Nat Biotechnol, 31, 787, 10.1038/nbt.2681